Agio


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Wikipedia.

Agio

 

a deviation toward a higher market price of gold than the quantity of paper money that nominally represents the given gold quantity.

Agio is usually computed as a percentage. Agio also means a deviation toward a higher market rate for paper money, promissory notes, and other securities than their face value. The deviation toward a lower rate is called disagio.

References in periodicals archive ?
Infinite Scalability: Agio SkySuite's technology environment can scale up as quickly and seamlessly as the client, without any interruption or the risks that come with having to change IT providers.
At Agio," McDonough continued, "we have always taken great pride in our high service standards and performance, and are continually challenging our team members to improve.
Solomon, of GOLDSMITH, AGIO, HELMS AND COMPANY, 612-339-0500/
The ability of a company like Agio to track hard results to company goals is part-and-parcel of why we believe scheduled communication is the lifeblood of the company.
These are the following Working Groups Group A: Supporting work lignite conveyor systems, plant chemistry and perform ancillary work in the above areas of SES Agios Dimitrios.
The connection between cancer and metabolism has been the central focus of scientists at Agios, who were the first to identify the neo-activity of IDH1 mutations to produce the oncometabolite 2-HG in research published in Nature in 2009.
Agios Pharmaceuticals and The University of Pennsylvania (Penn) have inked a licensing agreement for new intellectual property suitable for use to develop diagnostic products to identify certain cancer metabolisms.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.
Taken together, our talks illustrate the innovative research capabilities and the insights into novel targets in metabolism that make Agios a leader in the field.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, announced today a recent publication that highlights the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo.
ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announced that ChemPartner scientists are pleased to have been involved in recent groundbreaking cancer research from Agios Pharmaceuticals through the companies' ongoing partnership.